Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928220 | 1.00 | TSHR (0.47) | TSHRMAOBMAOARAB9AF2 | |
| SCHEMBL926155 | 1.00 | TSHR (0.47) | TSHRMAOBMAOARAB9AF2 | |
| SCHEMBL927464 | 0.97 | TSHR (0.47) | TSHRMAOBMAOARAB9AF2 | |
| SCHEMBL246286 | 0.96 | TSHR (0.50) | TSHRMAOBMAOARAB9AF2 | |
| SCHEMBL5093977 | 0.94 | MAOB (0.45) | TSHRMAOBMAOARAB9AF2 | |
| SCHEMBL14662625 | 0.92 | TSHR (0.51) | TSHRMAOBMAOARAB9AF2 | |
| SCHEMBL9763338 | 0.88 | TSHR (0.48) | TSHRMAOBMAOACYP1A2CYP2D6 | |
| SCHEMBL6633476 | 0.83 | MAOB (0.48) | TSHRMAOBMAOARAB9AF2 | |
| SCHEMBL924777 | 0.82 | TSHR (0.53) | TSHRMAOBMAOARAB9ACYP1A2 | |
| SCHEMBL6251727 | 0.81 | TSHR (0.59) | TSHRMAOBMAOAF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44874-E1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2014-04-29 | — | — | US | disclosed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8198483-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-7982067-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-7776895-B2 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| EP-2042168-A1 | Inhalation device comprising phenethanolamine derivatives for treatment of respiratory diseases | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| EP-1425001-B1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-7439393-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | disclosed |
| US-7361787-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-04-22 | — | — | US | disclosed |
| US-20080003290-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | US | disclosed |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| EP-1425001-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003024439-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003290-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | TSHR 3851/4885MAOB 557/4885MAOA 335/4885 |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PNMT, HRH2, CHKB | TSHR 1459/4885MAOB 853/4885MAOA 654/4885 |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | TSHR 3140/4885MAOB 406/4885MAOA 410/4885 |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | TSHR 3793/4885MAOB 455/4885MAOA 280/4885 |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | PNMT, CHRM3, HRH4 | TSHR 2181/4885MAOB 972/4885MAOA 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.